** Hong Kong-listed Lepu Biopharma 2157.HK jumps 14.2% to HK$2.73; set for biggest one-day pct gain since Dec. 17, 2024
** Stock hits highest since Dec. 27, 2024; on track for fifth consecutive session of gains
** Co grants exclusive global rights to ArriVent BioPharma AVBP.O to develop and commercialize Lepu's novel antibody drug conjugate candidate MRG007, which is used to treat gastrointestinal cancers, outside of Greater China
** Lepu will get one-time upfront and near-term milestone payments of $47 mln
** Eligible to get up to $1.16 bln in development, regulatory and sales milestones and tiered royalties in high single-digit to low-teen percentages on net sales in Licensed Region
** AVBP rose 3.7% on Tuesday
** Lepu fell ~38% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.